SCYNEXIS (SCYX) AI Stock Analysis

• Market Cap: $26.45M
• Dividend Yield: N/A
• Average Volume (3M): 612.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: -65.77%
• EPS Growth: 38.61%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.17
• Shares Outstanding: 41,924,942
• 10 Day Avg. Volume: 689,890
• 30 Day Avg. Volume: 612,753
• PEG Ratio: 0.02
• Price to Book (P/B): 1.07
• Price to Sales (P/S): 15.67
• P/FCF Ratio: -2.44
• Enterprise Value/Market Cap: -0.34
• Enterprise Value/Revenue: -3.06
• Enterprise Value/Gross Profit: -3.06
• Enterprise Value/Ebitda: -4.17
• 1Y Price Target: $3.50
• Price Target Upside: 446.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $0.50 ▼(-21.88% Downside)

SCYNEXIS's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue, profitability, and negative cash flow. Technical analysis provides a slightly better outlook but remains mixed. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events further limits positive influences on the score.

Positive Factors

Product Development

The successful Phase 1 study of SCY-247 indicates promising potential for a new antifungal treatment, which could enhance SCYNEXIS's product portfolio and market position in the long term.

Strategic Focus

By addressing resistant Candida infections, SCYNEXIS strengthens its niche in antifungal treatments, potentially leading to a competitive advantage in a critical area of infectious diseases.

Pipeline Advancement

Advancing to Phase 3 for invasive candidiasis treatment suggests progress in SCYNEXIS's pipeline, which could lead to new revenue streams and strengthen its market position.

Negative Factors

Revenue Decline

A significant decline in revenue indicates challenges in product sales and market penetration, potentially affecting SCYNEXIS's financial stability and growth prospects.

Negative Cash Flow

Persistent negative cash flow suggests liquidity issues, which could hinder SCYNEXIS's ability to invest in R&D and expand its operations, impacting long-term growth.

Profitability Challenges

Negative EBIT and EBITDA margins highlight operational inefficiencies and profitability challenges, which may limit SCYNEXIS's ability to sustain its business model and invest in future growth.

SCYNEXIS Business Overview & Revenue Model

Company Description

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

How the Company Makes Money

SCYNEXIS generates revenue primarily through the commercialization of its products, which may include sales from its lead antifungal therapy once it receives regulatory approval. Additionally, the company may also earn revenue through partnerships and collaborations with other pharmaceutical companies for research and development purposes, as well as milestone payments and royalties from any licensed products. Grants and funding for research initiatives may also contribute to the company's overall revenue stream, particularly in the early stages of product development.

SCYNEXIS Financial Statement Overview

Summary

SCYNEXIS faces multiple financial challenges with declining revenue and profitability, a moderately leveraged balance sheet, and negative cash flow trends. The company needs to address its operational inefficiencies and improve its cash flow to enhance financial stability.

Income Statement

SCYNEXIS shows significant volatility in its revenue and profitability. The revenue decreased sharply in 2024 from the previous year, and the company experienced a substantial net loss. The EBIT and EBITDA margins are negative, indicating operational challenges.

Balance Sheet

The company's balance sheet reflects a moderate debt-to-equity ratio and relatively stable stockholders' equity. However, the equity ratio is low, suggesting a higher reliance on liabilities, which could be risky.

Cash Flow

The cash flow situation is concerning, with negative free cash flow and operating cash flow. The company has not been able to generate positive cash flow from its operations, indicating a potential liquidity issue.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.93M	3.75M	140.14M	5.09M	13.16M	0.00
Gross Profit	2.93M	3.75M	124.52M	4.46M	12.85M	-303.00K
EBITDA	2.15M	-18.58M	70.89M	-59.91M	-32.91M	-55.65M
Net Income	-25.30M	-21.29M	67.04M	-62.81M	-32.87M	-55.19M
Balance Sheet
Total Assets	51.07M	90.64M	128.41M	87.81M	119.84M	102.54M
Cash, Cash Equivalents and Short-Term Investments	38.01M	59.30M	74.36M	73.50M	104.48M	93.04M
Total Debt	2.28M	16.27M	15.08M	48.60M	43.63M	19.84M
Total Liabilities	14.64M	35.57M	55.45M	84.58M	78.58M	79.78M
Stockholders Equity	36.43M	55.08M	72.96M	3.23M	41.26M	22.76M
Cash Flow
Free Cash Flow	-33.59M	-24.01M	60.16M	-79.89M	-55.73M	-49.36M
Operating Cash Flow	-33.59M	-24.01M	60.16M	-79.88M	-54.56M	-49.35M
Investing Cash Flow	33.51M	6.15M	-34.88M	-27.39M	-1.17M	6.47M
Financing Cash Flow	-14.21M	-139.00K	-36.72M	48.60M	67.12M	94.00M

SCYNEXIS Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Negative. The current price of 0.64 is below the 20-day moving average (MA) of 0.65, below the 50-day MA of 0.69, and below the 200-day MA of 0.83, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 42.77 is Neutral, neither overbought nor oversold. The STOCH value of 11.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCYX.

SCYNEXIS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CPIX	51 Neutral	$39.79M	-12.47	-13.08%	―	12.21%	69.91%
AYTU	48 Neutral	$21.11M	-0.76	-50.23%	―	-15.61%	-68.96%
TXMD	47 Neutral	$13.54M	-29.32	0.27%	―	75.19%	―
SCYX	46 Neutral	$26.45M	-1.11	-53.29%	―	-65.77%	38.61%
RMTI	44 Neutral	$36.84M	―	-16.67%	―	-23.60%	-179.33%
IMCC	42 Neutral	$9.13M	-2.21	-93.87%	―	-0.74%	81.49%

SCYNEXIS Corporate Events

SCYNEXIS and GSK Amend License Agreement

On October 14, 2025, SCYNEXIS and GSK signed a binding memorandum of understanding to amend their exclusive license agreement, resolving a prior disagreement over the Phase 3 MARIO study of ibrexafungerp. SCYNEXIS agreed to terminate the MARIO Study and will receive a $22 million payment from GSK, along with an additional $2.3 million for wind-down activities. GSK remains committed to the commercialization of BREXAFEMME® for VVC and rVVC, with plans to engage with the FDA in 2026 for its U.S. market relaunch. The agreement maintains the potential milestones and royalties for SCYNEXIS, excluding those related to the MARIO Study.